Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3294-3302

  Fecci, Peter E ^a   Mitchell, Duane A ^a   Whitesides, John F ^a   Xie, Weihua ^a   Friedman, Allan H ^a   Archer, Gary E ^a   Herndon II, James E ^a   Bigner, Darell D ^a   Dranoff, Glenn ^b   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOKINE PRODUCTION; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TH2 CELL; TUMOR ESCAPE; TUMOR REJECTION;

ADULT; AGED; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; FORKHEAD TRANSCRIPTION FACTORS; GLIOBLASTOMA; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 33645502885     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3773     Document Type: Article

References (36)

1. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999;100:216-32.
2. McVicar DW, Davis DF, Merchant RE. In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect. J Neurosurg 1992;76:251-60.
3. Ashkenazi E, Deutsch M, Tirosh R, Weinreb A, Tsukerman A, Brodie C. A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation. Neuroimmunomodulation 1997;4:49-56.
4. Roszman TL, Brooks WH. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 1980;39:395-402.
5. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol 1997;159:4415-25.
6. Roszman TL, Brooks WH, Steele C, Elliott LH. Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. J Immunol 1985;134:1545-50.
7. Elliott LH, Brooks WH, Roszman TL. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 1984;132:1208-15.
8. Ausiello CM, Palma C, Maleci A, et al. Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients. Eur J Cancer 1991;27:646-50.
9. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 1996;105:344-52.
10. Zou JP, Morford LA, Chougnet C, et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 1999;162:4882-92.
11. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
12. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96.
13. + T cell activation. Eur J Immunol 2003;33:3473-83.
14. + immunoregulatory cells. J Immunol 2001;167:1137-40.
15. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002;196:247-53.
16. + cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol 2004;172:5213-21.
17. + T cells to acquire regulatory cell function. Blood 2003;101:5076-83.
18. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
19. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-8.
20. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;161:4766-72.
21. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
22. + regulatory T cells. Int Immunol 2004;16:1643-56.
23. + T cells to dexamethasone-induced cell death. Eur J Immunol 2004;34:859-69.
24. Brooks WH, Roszman TL, Mahaley MS, Woosley RE. Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin Exp Immunol 1977;29:61-6.
25. Brooks WH, Roszman TL, Rogers AS. Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors. Cancer 1976;37:1869-73.
26. Mahaley MS, Jr., Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg 1977;46:467-76.
27. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005;62:1423-6.
28. Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M, Wharam M. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys 1999; 44:535-43.
29. + T-cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol 2003;171:4927-33.
30. de Martin R, Haendler B, Hofer-Warbinek R, et al. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 1987;6:3673-7.
31. Wrann M, Bodmer S, de Martin R, et al. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 1987;6:1633-6.
32. Munz C, Naumann U, Grimmel C, Rammensee HG, Weller M. TGF-β-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. Eur J Immunol 1999;29:1032-40.
33. + T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172:5149-53.
34. + regulatory T cells from human peripheral blood. J Immunol 2001;166:7282-9.
35. + T-cell pool and the expression of Foxp3 in vivo. Int Immunol 2004;16:1241-9.
36. Elliott L, Brooks W, Roszman T. Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 1987;78:919-22.